TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12468603

Group type: COMPARATOR
Intervention: Cracker only
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cracker with cream cheese
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral stimulation by fat
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Safflower oil capsules
Number of subjects: 25
Study: 10369171

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT) during hospital rehabilitation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Traditional rehabilitation services during hospitalization
Number of subjects: 59
Study: 7547095

Group type: EXPERIMENTAL
Intervention: Tenidap sodium (120 mg day‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tenidap sodium
Number of subjects: 18
Study: 2197394

Group type: EXPERIMENTAL
Intervention: Recovery Training and Self-help (RTSH)
Number of subjects: 168
Study: 7009093

Group type: EXPERIMENTAL
Intervention: Poly A. Poly U I.V. 30 mg per week for 6 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Normal saline I.V. on the same schedule
Number of subjects: 300
Study: 30514652

Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 746

Group type: COMPARATOR
Intervention: Prevention as usual
Number of subjects: 746
Study: 28692586

Group type: EXPERIMENTAL
Intervention: Extended-release metformin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26679879

Group type: EXPERIMENTAL
Intervention: Truview laryngoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 100
Study: 24749956

Group type: EXPERIMENTAL
Intervention: Nasogastric tube-guided technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 60
Study: 22723185

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening with removal of all detected lesions
Number of subjects: 68400

Group type: COMPARATOR
Intervention: No screening (standard of care)
Number of subjects: 68400
Study: 22166651

Group type: EXPERIMENTAL
Intervention: Insulin monotherapy
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Insulin plus metformin (0.5 g, tid)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Insulin plus metformin (0.5 g, tid) and pioglitazone (15 mg, qd)
Number of subjects: 147
Study: 17828060

Group type: EXPERIMENTAL
Intervention: Segmental stabilizing exercises (SSE)
Number of subjects: 100
Study: 16219190

Group type: EXPERIMENTAL
Intervention: Salmeterol-fluticasone
Number of subjects: 3421

Group type: COMPARATOR
Intervention: Fluticasone alone
Number of subjects: 3421
Study: 14529880

Group type: EXPERIMENTAL
Intervention: Tac and MMF (n = 41)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tac and Aza (n = 34)
Number of subjects: 75
Study: 11092645

Group type: EXPERIMENTAL
Intervention: HRT 2 (1 mg 17beta‐estradiol plus 0.025 mg gestodene for 12 days every third month)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: HRT 1 (1 mg 17beta‐estradiol plus 0.025 mg gestodene for 12 days every month)
Number of subjects: 321

Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 321
Study: 8636896

Group type: EXPERIMENTAL
Intervention: Participants expecting to perform a task alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants expecting to interact with another participant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants anticipating interaction with partners in neutral or good moods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants whose mood was not manipulated
Number of subjects: 0
Study: 1592282

Group type: EXPERIMENTAL
Intervention: Two intracavitary radium insertions
Number of subjects: 143

Group type: COMPARATOR
Intervention: One intracavitary radium insertion
Number of subjects: 143
Study: 6370492

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg bid
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 30516719

Group type: EXPERIMENTAL
Intervention: Right approach
Number of subjects: 150

Group type: COMPARATOR
Intervention: Left approach
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bilateral approach
Number of subjects: 150
Study: 29370538

Group type: EXPERIMENTAL
Intervention: OROS‐MPH
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 255
Study: 27171844

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.1 mg/kg twice/day for 12 months)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no oxandrolone)
Number of subjects: 54
Study: 24326527

Group type: EXPERIMENTAL
Intervention: Liraglutide (n=24)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 68
Study: 22459203

Group type: EXPERIMENTAL
Intervention: Randomised population of the NELSON trial
Number of subjects: 10627

Group type: EXPERIMENTAL
Intervention: Respondents of the first questionnaire
Number of subjects: 10627

Group type: EXPERIMENTAL
Intervention: Current smokers in the randomised population
Number of subjects: 10627

Group type: EXPERIMENTAL
Intervention: Current smokers in the respondents
Number of subjects: 10627
Study: 20045873

Group type: EXPERIMENTAL
Intervention: Life review intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (watching a video about the art of growing older)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 18823213

Group type: EXPERIMENTAL
Intervention: Native speakers of Sinhala
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Native speakers of German
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Native speakers of Dutch
Number of subjects: 3

Group type: COMPARATOR
Intervention: Perceptual interference
Number of subjects: 3
Study: 15917280

Group type: EXPERIMENTAL
Intervention: Education on oral anticoagulation, anticoagulation files, and patient information booklets; Group B received feedback every 2 months; Group C used CoaguChek device; Group D received Dawn AC computer assisted advice
Number of subjects: 66

Group type: COMPARATOR
Intervention: Education on oral anticoagulation, anticoagulation files, and patient information booklets
Number of subjects: 66
Study: 12546514

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid tablets 2.4 g/day and enema 2 g/day for 4 weeks
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid tablets 2.4 g/day and enema 2 g/day for 8 weeks
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Oral mesalazine alone at 1.2 g/day during maintenance period
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid tablets 2.4 g/day and enema 2 g/day for 8 weeks (specifically for left-sided colitis)
Number of subjects: 149
Study: 9849115

Group type: EXPERIMENTAL
Intervention: Antenatal Breastfeeding Workshops
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control (non-attendees)
Number of subjects: 159
Study: 7985276

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 17
Study: 2690913

Group type: EXPERIMENTAL
Intervention: Intravenous adriamycin 50 mg, vincristine 1 mg, cyclophosphamide 250 mg, methotrexate 150 mg and fluorouracil 250 mg (AVCMF) every 21 days for eight cycles
Number of subjects: 569

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 569
Study: 1155990

Group type: EXPERIMENTAL
Intervention: Tetrachlorethylene (T.C.E.) - single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bephenium hydroxynaphthoate - single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pyrantel pamoate - single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bephenium hydroxynaphthoate - three daily doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate - three daily doses
Number of subjects: 0
Study: 31901090

Group type: EXPERIMENTAL
Intervention: Cold analgesic technique
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anesthetic cream
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vibration analgesic technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-treatment arm (Control)
Number of subjects: 100
Study: 30880163

Group type: EXPERIMENTAL
Intervention: Naltrexone implant
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral naltrexone placebo
Number of subjects: 200
Study: 29283224

Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy (ART) using right cervical vagus nerve stimulation (VNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27421268

Group type: EXPERIMENTAL
Intervention: Promise of a monetary incentive at first mailout
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Promise on reminder letters only
Number of subjects: 1029
Study: 24997819

Group type: EXPERIMENTAL
Intervention: Periodontal ligament anesthesia using C‐CLADS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional manual submucosal infiltration anesthesia
Number of subjects: 50
Study: 22815970

Group type: EXPERIMENTAL
Intervention: Home-based aerobic interval training (AIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Residential rehabilitation
Number of subjects: 30
Study: 20615781

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl and propofol (group B)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Intravenous propofol (group A)
Number of subjects: 432
Study: 17572517

Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intravenous normal saline (placebo)
Number of subjects: 49
Study: 15744630

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclic Antidepressants (TCAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other SSRIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: TCAs and related ADs
Number of subjects: 0
Study: 12137859

Group type: EXPERIMENTAL
Intervention: hCG added urinary perfusion for 5 hours
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no hCG)
Number of subjects: 56
Study: 9457291

Group type: EXPERIMENTAL
Intervention: Puboprostatic ligament‐sparing technique
Number of subjects: 43
Study: 7621644

Group type: EXPERIMENTAL
Intervention: Non-invasive finger artery blood pressure (Finapres)
Number of subjects: 13
Study: 2524114

Group type: EXPERIMENTAL
Intervention: Combined therapy of diflunisal and cyclobenzaprine HCl
Number of subjects: 175

Group type: COMPARATOR
Intervention: Diflunisal
Number of subjects: 175

Group type: COMPARATOR
Intervention: Cyclobenzaprine HCl
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 71492

Group type: EXPERIMENTAL
Intervention: High-potency antilymphocyte globulin (A.L.G.)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Moderate-potency antilymphocyte globulin (A.L.G.)
Number of subjects: 71
Study: 6129872

Group type: EXPERIMENTAL
Intervention: Terfenadine (2 X 60 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clemastine (2 X 1 mg/day)
Number of subjects: 20
Study: 31626692

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion
Number of subjects: 372

Group type: COMPARATOR
Intervention: Control (no transfusion)
Number of subjects: 372
Study: 31361307

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN)
Number of subjects: 1128

Group type: COMPARATOR
Intervention: Early parenteral nutrition (PN)
Number of subjects: 1128
Study: 28222696

Group type: EXPERIMENTAL
Intervention: Transillumination-assisted technique (T group)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Midline approach technique (R group)
Number of subjects: 500
Study: 25912908

Group type: EXPERIMENTAL
Intervention: High Cadence Training (HCT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low Cadence Training (LCT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 36
Study: 23688096

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with vitamin E supplementation (200 mg every other day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) without vitamin E supplementation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (22 systemically and periodontally healthy individuals)
Number of subjects: 38
Study: 22412025

Group type: EXPERIMENTAL
Intervention: 400,000 IU of vitamin A
Number of subjects: 276

Group type: COMPARATOR
Intervention: 200,000 IU of vitamin A
Number of subjects: 276
Study: 19901116

Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg/d with antihypertensive prophylaxis
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cediranib 30 mg/d without antihypertensive prophylaxis
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cediranib 45 mg/d with antihypertensive prophylaxis
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cediranib 45 mg/d without antihypertensive prophylaxis
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All groups (cediranib 30 or 45 mg/d with or without antihypertensive prophylaxis)
Number of subjects: 126
Study: 17320580

Group type: EXPERIMENTAL
Intervention: 50 mL of autologous blood infused in the pleural cavity (Group A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 100 mL of autologous blood infused in the pleural cavity (Group B)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (Group C) - last 15 patients with air leaks for at least 6 days
Number of subjects: 25
Study: 15358853

Group type: EXPERIMENTAL
Intervention: CT angiography
Number of subjects: 145

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 145
Study: 12004696

Group type: EXPERIMENTAL
Intervention: Computerized system (the Wand)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 30
Study: 9459537

Group type: EXPERIMENTAL
Intervention: Individual Anaerobic Threshold (IAT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Anaerobic Threshold at 4 mmol lactate x l(‐1) (AT4)
Number of subjects: 10
Study: 8166474

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drugs
Number of subjects: 0
Study: 2973485

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA) plus immediate intervention (coronary angiography with a view to angioplasty)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 367
Study: 1089874

Group type: EXPERIMENTAL
Intervention: Parenteral idoxuridine at a dose of 100 mg per kilogram per day for five days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31238418

Group type: EXPERIMENTAL
Intervention: RIA-G software
Number of subjects: 229
Study: 27245786

Group type: EXPERIMENTAL
Intervention: Full-mouth non-surgical periodontal scaling during a single, untimed session
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 62
Study: 26241455

Group type: EXPERIMENTAL
Intervention: Dexamethasone (30 mg total dose)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dexamethasone with concomitant infection
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Angle fractures
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 37
Study: 23639212

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 19921347

Group type: EXPERIMENTAL
Intervention: Children with autism (AU)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Typically developing controls (TD)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Children with autism (AU) and Typically developing controls (TD)
Number of subjects: 52
Study: 19299346

Group type: EXPERIMENTAL
Intervention: 2 mL of autologous blood alone (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2 mL of lidocaine combined with peppering (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2 mL of triamcinolone alone (Group C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2 mL of triamcinolone combined with peppering (Group D)
Number of subjects: 100
Study: 17092376

Group type: EXPERIMENTAL
Intervention: Lower loaf volume of white bread
Number of subjects: 10
Study: 15065222

Group type: EXPERIMENTAL
Intervention: Sodium valproate (starting dose of 2 × 6 ml of a 40 mg/ml suspension, daily defined dose of 480 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 39
Study: 10100082

Group type: EXPERIMENTAL
Intervention: MDL 100,240 (6.25 mg and 25 mg doses)
Number of subjects: 12
Study: 9286316

Group type: EXPERIMENTAL
Intervention: Bifocal lenses (+1.25 D)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single-vision lenses
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 1997185

Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 50 mg/m2/120 h
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 75 mg/m2/120 h
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 100 mg/m2/120 h
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 87.5 mg/m2/120 h
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 75 mg/m2 or more
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S)
Number of subjects: 15
Study: 31461120

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 0
Study: 28963710

Group type: EXPERIMENTAL
Intervention: PreSET
Number of subjects: 25
Study: 27912944

Group type: EXPERIMENTAL
Intervention: Acupressure on LI4
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Acupressure on BL32
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (routine labor care only)
Number of subjects: 105
Study: 24225337

Group type: EXPERIMENTAL
Intervention: Reduction in RV end-systolic area (RV-ESA) >20%
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Subjective clinical improvement at 6 months
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Composite endpoint including death and admission for right heart failure
Number of subjects: 61
Study: 23136915

Group type: EXPERIMENTAL
Intervention: RS+P (resistant starch + pullulan)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SCF (soluble corn fiber)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SCF+P (soluble corn fiber + pullulan)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (low-fiber control breakfast)
Number of subjects: 20
Study: 20078464

Group type: EXPERIMENTAL
Intervention: REMAS intervention (five sessions including information, motivational exercises, and skills training)
Number of subjects: 277

Group type: COMPARATOR
Intervention: HIV education (HIV‐Ed; one session containing HIV prevention information)
Number of subjects: 277
Study: 18462858

Group type: EXPERIMENTAL
Intervention: Continuous mode (CM) at 5.0 W
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5.0 W
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cervical third of the root
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups after 30s post-irradiation
Number of subjects: 90
Study: 15702816

Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg for children <11 years; 400 microg for those ≥11 years)
Number of subjects: 7221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7221

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 7221
Study: 14501543

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Nontailored intervention
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 1325
Study: 10812218

Group type: EXPERIMENTAL
Intervention: Varicella vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated susceptibles
Number of subjects: 0
Study: 8664845

Group type: EXPERIMENTAL
Intervention: Maximal Anaerobic Running Test (MART)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Maximal Accumulated Oxygen Deficit (MAOD)
Number of subjects: 18
Study: 1839144

Group type: EXPERIMENTAL
Intervention: Monthly treatment with ethinyl estradiol (30 micrograms/day) plus desogestrel (150 micrograms/day) in three-week cycles every month
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bimonthly treatment with ethinyl estradiol (30 micrograms/day) plus desogestrel (150 micrograms/day) in three-week cycles every other month
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study: 6222388

Group type: EXPERIMENTAL
Intervention: 100 mg b.i.d. zimelidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 75 mg b.i.d. clomipramine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Norzimelidine (desmethylated metabolite of zimelidine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clomipramine and desmethylclomipramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (age and sex matched)
Number of subjects: 10
Study: 31481039

Group type: EXPERIMENTAL
Intervention: Walking Exercise Group (WEG; achieving 12,000 steps per day, including 3 days per week on which walking at a step rate of over 103 steps min⁻¹ was required)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Walking Step Goal Group (WSG; achieving 12,000 steps per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control Group (CG; maintaining a free-living lifestyle)
Number of subjects: 32
Study: 28902880

Group type: EXPERIMENTAL
Intervention: School-based Education Program to Reduce Salt Intake
Number of subjects: 28
Study: 27175681

Group type: EXPERIMENTAL
Intervention: Essence of Chicken (EC) 70 mL daily for 2 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Essence of Chicken (EC)
Number of subjects: 102
Study: 24585267

Group type: EXPERIMENTAL
Intervention: Diuretic response (Δ weight kg/40 mg furosemide)
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: Poor diuretic response
Number of subjects: 1745
Study: 23244449

Group type: EXPERIMENTAL
Intervention: E-health4Uth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-health4Uth + counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0